Soleus continues to lead the recovery in what had been one of the year’s most beaten-down sectors.
Stephen TaubDecember 14, 2022
(Lauryn Ishak/Bloomberg)
After suffering sharp losses in the first half of the year, biopharma-focused hedge funds continued to bounce back last month. Several of them are now either in the black, at breakeven, or close to breakeven heading into the
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.